Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
5(83.3%)
Phase 1
1(16.7%)
6Total
Phase 2(5)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06013839Phase 2Unknown

TXA127 in Non-Ambulant Patients With DMD Cardiomyopathy

Role: lead

NCT06135103Phase 2Unknown

Phase 2 Study of TXA127 in Post-ischemic Stroke Patients

Role: lead

NCT04401423Phase 2Completed

TXA127 for the Treatment of Severe COVID-19

Role: collaborator

NCT04605887Phase 2Unknown

Angiotensin 1-7 as a Therapy in the Treatment of COVID-19

Role: collaborator

NCT01300611Phase 1Terminated

TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation

Role: collaborator

NCT01121120Phase 2Terminated

Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients

Role: collaborator

All 6 trials loaded